Adaptimmune Ltd.

116 articles with Adaptimmune Ltd.

• Two Confirmed Responses and Five out of Six Patients with Initial Tumor Reductions from Early Dose Cohorts of SURPASS Trial, Presented at SITC

  11/9/2020

  Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, presented data from the dose escalation cohorts of its Phase 1 SURPASS trial using ADP-A2M4CD8 in a poster at the Society for the Immunotherapy of Cancer Conference.

• Adaptimmune Reports Q3 Financial Results and Business Update

  11/5/2020

  - Data from Phase 1 Trial with ADP-A2AFP in liver cancer presented at ILC confirm safety profile and demonstrate potential benefit for patients - - Safety and response data from dose escalation cohorts of the SURPASS trial to be presented at SITC - - Durability of response data from patients with synovial sarcoma from the Phase 1 ADP-A2M4 trial to be presented at CTOS - - Virtual Investor Day planned for November 20, 2020 - - Financial guidance confirmed: funded into 2022 -

• Adaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS Trial

  10/15/2020

  Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in cell therapy to treat cancer is aware of the early release of the abstract entitled “Initial safety, efficacy, and product attributes from the SURPASS trial with ADPA2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor” by the Society for the Immunotherapy of Cancer (“SITC”) Conference

• Adaptimmune Reports Q2 Financial Results and Business Update

  8/6/2020

  - Reported responses in multiple solid tumor types during ASCO with updates at upcoming congresses in Q4 - - Continued progress toward launch of ADP-A2M4 for sarcoma in the US in 2022 with ongoing enrollment of patients in SPEARHEAD-1 - - Granted access to PRIority MEdicines (PRIME) regulatory support by the European Medicines Agency for ADP-A2M4 for the treatment of synovial sarcoma - - Completed public offering with net proceeds of approximately $244m; guidance confirmed: funded into 2022

• Adaptimmune to Report Q2 Financial Results and Business Update on Thursday, August 6, 2020

  7/22/2020

  Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for Q2 2020, before the U.S. markets open on Thursday, August 6, 2020. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EDT (1:00 p.m. BST) on the same day (details below). The press release and the live webcast of the con

• Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary Shares - June 04, 2020

  6/4/2020

  PHILADELPHIA and OXFORDSHIRE, United Kingdom, June 04, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in cell therapy to treat cancer, today announced the closing of its previously announced underwritten public offering of its American Depositary Shares (“ADSs”).  Adaptimmune sold a total of 23,575,000 ADSs at a price to the public of $11.00 per ADS, including 3,075,000 ADSs pursuant to the exercise in full by the underwriters of their option to p

• Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares - June 02, 2020

  6/2/2020

  Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, announced the pricing of an underwritten public offering of 20,500,000 of its American Depositary Shares at a price to the public of $11.00 per ADS.

• Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares - Jun 01, 2020

  6/1/2020

  Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, announced that it intends to offer and sell 12,500,000 American Depositary Shares in an underwritten public offering.

• Adaptimmune Reports Q1 Financial Results

  5/14/2020

  - Upfront payment of $50m received from Astellas and approximately $90m offering completed -             - Financial guidance confirmed: funded into 2H 2021 - - Orphan Drug Designation positive opinion for ADP-A2M4 in the EU adds to US FDA ODD and RMAT designations - - Upcoming presentations at major scientific meetings with data from ADP-A2M4, ADP-A2AFP, and allogeneic programs - - Conference call to be held today at 8:00 a.m. EDT (1:00 p.m. BST) - PHILADELPHIA and OXFORDSHIRE, United Kin

• SPEAR T-cells Derived from Stem-Cells Kill Cancer Targets - Adaptimmune Presents Advances from its Allogeneic Platform at ASGCT Annual Meeting

  5/12/2020

  Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, presented advances from its “off-the-shelf” or allogeneic platform at the American Society for Gene and Cell Therapy Annual meeting which kicked off in virtual format.

• 

  BioSpace Global Roundup, April 30

  4/30/2020

  Biopharma companies from across the globe provide updates on their business and pipelines.

• Adaptimmune to Report Q1 Financial Results on Thursday, May 14, 2020

  4/29/2020

  Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results for Q1 2020, before the U.S. markets open on Thursday, May 14, 2020. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EDT (1:00 p.m. BST) on the same day (details below). The pres

• Positive Opinion for Orphan Drug Designation for ADP-A2M4 in the European Union for the Treatment of Soft Tissue Sarcoma from EMA' Committee of Orphan Medicinal Products

  4/28/2020

  Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, announced that the European Medicine Agency’s Committee for Orphan Medicinal Products has adopted a positive opinion for Orphan Drug Designation for ADP-A2M4 for the treatment of soft tissue sarcomas.

• Adaptimmune Reports Fourth Quarter / Full Year 2019 Financial Results and Business Update

  2/27/2020

  - Compelling data in synovial sarcoma in the Phase 1 trial, and continued momentum in the Phase 2 SPEARHEAD-1 trial with goal to launch ADP‑A2M4 for sarcoma in 2022 -

• Adaptimmune to Report Full Year / Q4 2019 Financial Results and Business Update on Thursday, February 27, 2020

  2/20/2020

  Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, will report financial results for the Full Year / Fourth Quarter 2019 and provide a business update, before the U.S. markets open on Thursday, February 27, 2020.

• Adaptimmune Therapeutics plc Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional American Depositary Shares

  2/7/2020

  PHILADELPHIA, Pa. and OXFORD, United Kingdom, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that the underwriters of its previously announced public offering of 21,000,000 American Depositary Shares (“ADSs”), which initially closed on January 24, 2020, have exercised in full their option to purchase an additional 3,150,000 of its ADSs at a price to the public of $4.00 per ADS, raising a

• 

  Liver Cancer Insight Report: Current Therapies, Drug Pipeline and Outlook

  1/29/2020

  Incidence rates for liver cancer began rising in the mid-1970s, and they are expected to go up through at least 2030. This report aims to give an overview of liver cancer, as well as explore current therapies, drugs in the pipeline and the future treatment landscape for patients and their caregiv...

• Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary Shares

  1/24/2020

  Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, announced the closing of its previously announced underwritten public offering of its American Depositary Shares.

• Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares

  1/21/2020

  Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, announced that it intends to offer and sell American Depositary Shares in an underwritten public offering.

• 

  Clinical Catch-Up: January 13-17

  1/20/2020

  There were plenty of clinical trial announcements this week. Here's a look.